में अनुक्रमित
- जे गेट खोलो
- जेनेमिक्स जर्नलसीक
- शैक्षणिक कुंजी
- अनुसंधान बाइबिल
- RefSeek
- रिसर्च जर्नल इंडेक्सिंग की निर्देशिका (डीआरजेआई)
- हमदर्द विश्वविद्यालय
- ईबीएससीओ एज़
- ओसीएलसी- वर्ल्डकैट
- विद्वान्
- पबलोन्स
- यूरो पब
- गूगल ज्ञानी
उपयोगी कड़ियां
इस पृष्ठ को साझा करें
जर्नल फ़्लायर
एक्सेस जर्नल खोलें
- अभियांत्रिकी
- आनुवंशिकी एवं आण्विक जीवविज्ञान
- इम्यूनोलॉजी और माइक्रोबायोलॉजी
- औषधि विज्ञान
- कृषि और जलकृषि
- चिकित्सीय विज्ञान
- जीव रसायन
- जैव सूचना विज्ञान और सिस्टम जीवविज्ञान
- तंत्रिका विज्ञान और मनोविज्ञान
- नर्सिंग एवं स्वास्थ्य देखभाल
- नैदानिक विज्ञान
- पदार्थ विज्ञान
- पर्यावरण विज्ञान
- पशु चिकित्सा विज्ञान
- भोजन एवं पोषण
- रसायन विज्ञान
- व्यवसाय प्रबंधन
- सामान्य विज्ञान
अमूर्त
In vitro susceptibility of fosfomycin against Extended-Spectrum β-lactamase-producing Escherichia coli isolated from urine specimens
Na Wu, Bai Yi Chen,Su Fei Tian and Yun Zhuo Chu
Background: The production of extended-spectrum β-lactamases (ESBLs) brings challenge to the treatment of urinary infection caused by Escherichia coli with increasing resistance to common antibiotics. For the limited treatment option, fosfomycin as traditional antibiotic has been reevaluated. Yet there are scarce studies regarding the antibacterial activity of fosfomycin for urinary infection in China. With this regard, we investigated in vitro susceptibility of fosfomycin and other 7 agents against ESBLs-producing Escherichia coli isolated from urine specimens.
Methods: The minimum inhibitory concentrations (MICs) of fosfomycin and other comparative agents including meropenem, piperacillin-tazobactam, amikacin, cefepime, cefotaxime, ceftazidime and levofloxacin were determined by agar dilution method recommended by the Clinical Laboratory Standards Institute (CLSI) 2010.
Results: Of the 100 strains isolated from urine, none was found resistant to meropenem .The relatively high susceptibility was found to piperacillin-tazobactam (94%), amikacin (85%), fosfomycin (82%) and cefepime (60%). The susceptibility rate of fosfomycin did not differ significantly between the cefotaxime-resistant (CTX-R) and cefotaxime-susceptible (CTX-S) group (80.1% vs 84.6%, P=0.712), ceftazidime-resistant (CAZ-R) and ceftazidime-susceptible (CAZ-S) group (78.1% vs 84.8%, P=0.552), levofloxacin-resistant (LVX-R) and levofloxacin-susceptible (LVX-S) group (85.4% vs 62.5%, P=0.07) respectively.
Conclusions: For the relatively high antibacterial activity in vitro against ESBLs-producing Escherichia coli isolated from urine specimens and the non-influenced by the pattern of resistance to other antimicrobials, fosfomycin is of great clinical value in the treatment of uncomplicated urinary infection caused by ESBLs-producing Escherichia coli.